Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Benefits advisors today are navigating a complex pharmacy benefits market with many opaque practices and hidden pitfalls.
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
A recognized expert in healthcare technology, Ravi Kottur explores how artificial intelligence (AI) is transforming Pharmacy ...
In this Q&A, Joe Dorazio, Small Group Head of Sales – at Aetna ®, a CVS Health ® Company, addresses common questions about ...
Bank of America Securities analyst Allen Lutz reiterated a Sell rating on Walgreens Boots Alliance (WBA – Research Report) today and set a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback